What Has Been The Evolution of the Adenosine DeaminaseSevere Combined Immunodeficiency Market in Recent Years?
The adenosine deaminasesevere combined immunodeficiency market has seen considerable growth due to a variety of factors.
• In recent times, the adenosine deaminase-severe combined immunodeficiency industry has shown intensive growth. The market size is projected to rise from it's 2024 value of $5.57 billion to reach $5.95 billion in 2025, maintaining a compound annual growth rate (CAGR) of 6.9%.
This substantial growth during the period can be credited to several factors including a higher occurrence of severe combined immunodeficiency, rising incidents of PID, an increase in recorded immunodeficiencies, more investment into healthcare, and a growing consciousness of immunodeficiencies.
How Will the Adenosine DeaminaseSevere Combined Immunodeficiency Market Size Evolve over the Forecast Period?
The adenosine deaminasesevere combined immunodeficiency market is expected to maintain its strong growth trajectory in upcoming years.
• The market for adenosine deaminase-severe combined immunodeficiency is predicted to experience significant growth in the coming years, reaching $7.70 billion by 2029 with a compound annual growth rate (CAGR) of 6.6%.
The anticipated growth can be credited to a surge in genetic disorders, an increase in the use of bone marrow transplantation, a growing demand for non-conditioned stem cell transplantation, a higher incidence of ADA deficiency, and an uptick in the number of adenosine deaminase deficiencies (PDA). Advanced technological developments, acceptance of gene therapy, governmental efforts, improvements in genetic testing, and biotechnology progress are some of the major trends projected for the forecast period.
Which Factors Are Boosting Growth In The Adenosine DeaminaseSevere Combined Immunodeficiency Market?
The escalating occurrence of genetic anomalies is anticipated to drive the expansion of the adenosine deaminase-severe combined immunodeficiency market in the future. Genetic irregularities are health issues triggered by deformities or changes within a person's DNA, which are either inherited or spontaneously develop. Numerous factors contribute to the increasing occurrence of these disorders, including enhanced diagnostic tools, heightened awareness, the rising age of parents, environmental impacts, and population growth. The growing occurrence of these anomalies, specifically adenosine deaminase-severe combined immunodeficiency (ADA-SCID), sparks a greater demand for advanced diagnostic techniques and specialised treatment. For example, a UK government department, the Department of Health & Social Care (DHSC), released a report in December 2022 stating that around 33,000 full genome equivalents were sequenced as of October 2022, with an average diagnostic yield of 32%, rising to 61% for specific conditions. Consequently, the escalating occurrence of genetic anomalies is propelling the expansion of the adenosine deaminase-severe combined immunodeficiency market.
What Key Areas Define The Segmentation Of The Global Adenosine DeaminaseSevere Combined Immunodeficiency Market?
The adenosine deaminase-severe combined immunodeficiency market covered in this report is segmented –
1) By Treatment Type: Enzyme Replacement Therapy (ERT), Gene Therapy, Stem Cell Transplantation, Supportive Care Treatments
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Age Group: Pediatric (Infants and Children), Adults
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Others End-Users
Subsegments:
1) By Enzyme Replacement Therapy (ERT): Adenosine Deaminase Enzyme Replacement, Pegylated Erythropoietin (PEG-EPO)
2) By Gene Therapy: Autologous Stem Cell-Based Gene Therapy, Viral Vector-Mediated Gene Therapy
3) By Stem Cell Transplantation: HLA-Matched Bone Marrow Transplant, Umbilical Cord Blood Transplant
4) By Supportive Care Treatments: Antimicrobial Therapy, Immune System Support, Nutritional Support
Pre-Book The Adenosine DeaminaseSevere Combined Immunodeficiency Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Adenosine DeaminaseSevere Combined Immunodeficiency Market?
Primary businesses in the adenosine deaminase-severe combined immunodeficiency market are directing their efforts towards novel treatments such as gene therapy for rare illnesses to elevate the results of the treatment, boost patient lifespan, and tackle the root genetic causes of these conditions using cutting-edge medical procedures. ADA-SCID gene therapy aims to rectify the genetic anomaly by infusing a workable copy of the ADA gene; this is hoped to offer a long-term remedy for those afflicted by this uncommon, fatal immune condition. For instance, in May 2022, life sciences and diagnostics innovator company Danaher Corporation, based in the US, became part of the Bespoke Gene Therapy Consortium (BGTC) which operates under the Accelerating Medicines Partnership (AMP) program. Working in association with the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), pharmaceutical businesses, and non-profit groups, this initiative is focused on propelling the advancement of customized gene therapies for rare conditions and improving the efficiency of their development. This collaboration holds particular importance as it symbolizes a joint effort to tackle the obstacles of conventional drug creation for rare diseases—conditions which often go disregarded in the commercial space due to their rare incidence.
Who Are the Key Players In The Adenosine DeaminaseSevere Combined Immunodeficiency Market?
Major companies operating in the adenosine deaminase-severe combined immunodeficiency market are:
• Novartis AG
• GlaxoSmithKline plc (GSK)
• Astellas Pharma
• Orient EuroPharma
• Charles River Laboratories
• Chiesi Farmaceutici S.p.A.
• Spark Therapeutics
• Rocket Pharmaceuticals
• Bluebird Bio
• Ospedale San Raffaele (OSR)
• Oxford Biomedica PLC
• Teijin Pharma
• Leadiant Biosciences
• Orchard Therapeutics PLC
• Fondazione Telethon
• Mustang Bio Inc
• Sigma-Tau Pharmaceuticals
• Shenzhen Geno-Immune Medical Institute
• ENZON Pharmaceuticals
• QED Bioscience Inc.
What Is The Most Dominant Region In The Adenosine DeaminaseSevere Combined Immunodeficiency Market?
North America was the largest region in the adenosine deaminase-severe combined immunodeficiency market in 2024. The regions covered in the adenosine deaminase-severe combined immunodeficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
